Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 11
1991 21
1992 23
1993 26
1994 27
1995 42
1996 49
1997 39
1998 33
1999 44
2000 60
2001 57
2002 55
2003 65
2004 61
2005 67
2006 69
2007 60
2008 64
2009 59
2010 64
2011 59
2012 62
2013 48
2014 56
2015 72
2016 50
2017 52
2018 54
2019 59
2020 60
2021 51
2022 41
2023 43
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,574 results

Results by year

Filters applied: . Clear all
Page 1
Update on T-Cell Lymphoma Epidemiology.
Chen JJ, Tokumori FC, Del Guzzo C, Kim J, Ruan J. Chen JJ, et al. Curr Hematol Malig Rep. 2024 Jun;19(3):93-103. doi: 10.1007/s11899-024-00727-w. Epub 2024 Mar 7. Curr Hematol Malig Rep. 2024. PMID: 38451372 Review.
Collaborative efforts on prospective registries based on the most current WHO classifications will help capture the true epidemiology of TCL subtypes to better focus resources for diagnostic, prognostic, and therapeutic efforts....
Collaborative efforts on prospective registries based on the most current WHO classifications will help capture the true epidemiology of TCL …
Central Nervous System Lymphoma.
Chukwueke UN, Nayak L. Chukwueke UN, et al. Hematol Oncol Clin North Am. 2019 Aug;33(4):597-611. doi: 10.1016/j.hoc.2019.03.008. Epub 2019 May 10. Hematol Oncol Clin North Am. 2019. PMID: 31229157 Review.
Angioimmunoblastic T-cell lymphoma.
Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH. Iannitto E, et al. Crit Rev Oncol Hematol. 2008 Dec;68(3):264-71. doi: 10.1016/j.critrevonc.2008.06.012. Epub 2008 Aug 6. Crit Rev Oncol Hematol. 2008. PMID: 18684638 Review.
Almost all cases arbor an EBV infected B-cell population. Patients with AITL have a poor prognosis with conventional treatment, with a median overall survival of less than 3 years. ...
Almost all cases arbor an EBV infected B-cell population. Patients with AITL have a poor prognosis with conventional treatment, with …
Massive Splenomegaly.
Rashidi A, Courville E. Rashidi A, et al. N Engl J Med. 2019 Aug 8;381(6):e11. doi: 10.1056/NEJMicm1901064. N Engl J Med. 2019. PMID: 31390503 No abstract available.
Nasal T-cell lymphoma.
Weiss LM, Arber DA, Strickler JG. Weiss LM, et al. Ann Oncol. 1994;5 Suppl 1:39-42. doi: 10.1093/annonc/5.suppl_1.s39. Ann Oncol. 1994. PMID: 8172815 Review.
Treatment of T-cell non-Hodgkin's lymphoma.
Evens AM, Gartenhaus RB. Evens AM, et al. Curr Treat Options Oncol. 2004 Aug;5(4):289-303. doi: 10.1007/s11864-004-0020-8. Curr Treat Options Oncol. 2004. PMID: 15233906 Review.
Targeting epigenetic regulators in the treatment of T-cell lymphoma.
Ahmed N, Feldman AL. Ahmed N, et al. Expert Rev Hematol. 2020 Feb;13(2):127-139. doi: 10.1080/17474086.2020.1711732. Epub 2020 Jan 22. Expert Rev Hematol. 2020. PMID: 31903826 Free PMC article. Review.
Critical next steps for the field include optimizing combination therapies that incorporate epigenetic-modifying agents and developing predictive biomarkers that help guide patient and drug selection....
Critical next steps for the field include optimizing combination therapies that incorporate epigenetic-modifying agents and developing pr …
1,574 results